3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase EARLY_PHASE1
2
Phase 1/2
2
Phase 1
2
Phase NA
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Lung Neoplasms
58
Carcinoma, Non-Small-Cell Lung
53
Breast Neoplasms
19
Pancreatic Neoplasms
11
Small Cell Lung Carcinoma
9
Ovarian Neoplasms
9
Melanoma
9
Colorectal Neoplasms
8
Colonic Neoplasms
8
Stomach Neoplasms
7
Sarcoma
7
Head and Neck Neoplasms
7
Neoplasms
6
Pleural Effusion, Malignant
5
Mesothelioma
5
Carcinoma, Renal Cell
5
Urinary Bladder Neoplasms
4
Adenocarcinoma of Lung
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Osteosarcoma
3
Neoplasm Metastasis
3
Glioblastoma
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Brain Neoplasms
3
Rectal Neoplasms
2
Pulmonary Disease, Chronic Obstructive
2
NSCLC
2
Interventions
Atovaquone
1
3-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Hypoxia
×
Thoracic
×
Clear all
NCT02628080
2019-09-04
ATOM
University of Oxford
Phase EARLY_PHASE1
Completed
46 enrolled
NCT00884520
2010-03-16
VM4-037
Siemens Molecular Imaging
Phase EARLY_PHASE1
Completed
16 enrolled